Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback